Aivita Biomedical, Inc.
Quick facts
Marketed products
- MC · Regenerative Medicine / Tissue Repair
MC is a mesenchymal stem cell (MSC) therapy that promotes tissue repair and regeneration through immunomodulation and paracrine signaling.
Phase 3 pipeline
- Autologous monocytes · Immunology; Regenerative Medicine
Autologous monocytes are a patient's own immune cells that are isolated, potentially modified or activated ex vivo, and reinfused to enhance immune function and promote tissue repair. - AV-GBM-1 · Oncology
AV-GBM-1 is an autologous dendritic cell vaccine designed to stimulate the patient's immune system to recognize and attack glioblastoma tumor cells.
Phase 2 pipeline
- AVOVA-1 · Regenerative Medicine / Immunology
AVOVA-1 is an allogeneic cell therapy derived from umbilical cord tissue that aims to promote tissue regeneration and reduce inflammation.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Aivita Biomedical, Inc.
What are Aivita Biomedical, Inc.'s marketed drugs?
Top marketed products include MC.
What is Aivita Biomedical, Inc.'s pipeline?
Aivita Biomedical, Inc. has 2 drugs in Phase 3, 1 in Phase 2, 1 in Phase 1. Late-stage candidates include Autologous monocytes, AV-GBM-1.
Related
- MC · Regenerative Medicine / Tissue Repair
- Sector hub: All tracked pharma companies